Company intelligence / Profile preview

Oleoyl-Estrone Developments

Ownership: Private
Development stage: Phase 2

Overview

Oleoyl-Estrone Developments was founded to develop oleoyl estrone as an anti-obesity therapeutic. The compound showed initial promise in preclinical and early clinical studies for weight loss without dietary restriction. However, Phase 2a studies failed to show statistically significant or clinically meaningful weight loss compared to placebo. As a result, the program was discontinued and the company became defunct.

Therapeutic areas: Endocrinology
Modalities: Small moleculesfatty acid esters of estrone
Industry: Biotech

Drug pipeline

1 asset

oleoyl-estrone

Phase 2

Indications: Obesity

Partnerships

Manhattan Pharmaceuticals licensed exclusive worldwide rights to OE from Oleoyl-Estrone Developments in 2002 for further development and commercialization efforts.

Beyond the preview

Go deeper on Oleoyl-Estrone Developments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oleoyl-Estrone Developments.

Explore the full profile